The Evolving Treatment Landscape of Acid-Related Disorders: The Role of New and Emerging Potassium-Competitive Acid Blocker Therapies (Pharmacy Technician Credit)

Program Description
Across the United States, up to 70 million people are affected by acid-related disorders, including Helicobacter pylori infection, gastroesophageal reflux disease, and its more serious form, erosive esophagitis. Acid-related disorders result in greater health-related quality of life burden for patients, and treatment of these conditions has been limited by antibiotic resistance, adverse effects, treatment regimens, and disease recurrence. The recent approval of a potassium-competitive acid blocker (PCAB) with a differentiated mechanism of action from proton pump inhibitors may overcome these challenges. Pharmacists must understand current practice guideline recommendations for treatment and prevention of complications of acid-related disorders as well as the safety and efficacy data for PCAB therapy and ongoing clinical studies for its use across other digestive diseases. Dosing recommendations, management of potential adverse effects and drug interactions, and counseling points for pharmacists to improve medication adherence and health-related quality of life using PCAB therapy will also be addressed.

Target audience: Pharmacy technicians

Type of activity: Knowledge
Release date: August 1, 2023
Expiration date: August 1, 2024

Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Recognize the disease burden and current unmet needs in the treatment landscape of acid-related disorders
• Recall the rationale for use and potential adverse effects of new and emerging potassium-competitive acid blockers (PCABs)
• Indicate the role of pharmacy technicians in assisting the pharmacist with optimizing the management of patients with acid-related disorders by ensuring proper use of the novel PCABs and approaches for improving adherence and adverse effect management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-23-314-H01-T. The activity is available for CE credit through August 1, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Shubha Bhat, PharmD, MS, FCCP, BCACP, has the following relevant financial relationships with commercial interests to disclose:

Advisory Boards: Pfizer, Bristol Myers Squibb, Boehringer Ingelheim, Prometheus Lab, Pharmacosmos

Speakers Bureau: Prometheus Lab

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Michelle C. Carlson, PharmD; Crissy Wilson; Abigail Dill; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms